issue contents
November 2018 issue
![Highlighted illustration](/x/issues/2018/11/00/graphics/coverill.gif)
Cover illustration: D3-Trishomocubane and its derivatives are of interest for their use as targets for pharmaceutical applications and in medicinal chemistry as well as in asymmetric catalysis. Several amino functionalized D3-trishomocubane derivatives show significant biological activity and are NMDA receptor antagonists. In addition, some of them exhibit potent anti-TB activity, act as P2X7 receptor antagonists and exhibit anti-Parkinson's activity. The cage compound spiro[cyclopentane-1,11'-hexacyclo[7.6.0.01,6.06,13.08,12.010,14]pentadecane]-7',15'-dione was prepared from cheap and commercially available starting materials such as 1,4-hydroquinone in eight steps via Claisen rearrangement, Diels-Alder reaction and ring-closing metathesis (RCM) followed by acid-promoted rearrangement with Lewis acid. See: Kotha, Gunta, Cheekatla & Mhatre [IUCrData (2017). 3, x181590].
inorganic compounds
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
metal-organic compounds
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![\overline{1}](/x/issues/2018/11/00/zq4032/teximages/zq4032fi1.gif)
organic compounds
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)
![cross.png](/logos/buttonlogos/cross.png)
![cross.png](/logos/buttonlogos/cross.png)
![Open Access](/logos/open.png)